Диссертация (1091769), страница 24
Текст из файла (страница 24)
Biomol. Chem. — 2007. — Vol. 5. —No 18. — P. 2884—2890.69)Steer, D.L. Beta-amino acids: versatile peptidomimetics [Text] / D.L. Steer,R.A. Lew, P. Perlmutter, A.I. Smith, M.I. Aguilar // Curr. Med. Chem. — 2002. —Vol. 9. — No 8. — P. 811—822.70)Wiegand, H. The outstanding metabolic stability of a 14C-labeled beta-nonapeptide in rats-in vitro and in vivo pharmacokinetic studies [Text] / H. Wiegand, B.Wirz, A. Schweitzer, G.P. Camenisch, M.I. Rodriguez Perez, G. Gross // Biopharm.Drug Dispos.
— 2002. — Vol. 23. — No 6. — P. 251—262.14371)Kasperkiewicz, P. Current and prospective applications of non-proteinogenic amino acids in profiling of proteases substrate specificity [Text] / P.Kasperkiewicz, A.D. Gajda, M. Drąg // Biol. Chem. — 2012. — Vol. 393. — No 9. —P. 843—851.72)(GnRHR).Gonadotropin-releasing Hormone (GnRH) and the GnRH receptor[ЭлектронныйРесурс]//GLOWM:[сайт]:—URL:http://www.glowm.com/section_view/heading/Gonadotropinreleasing%20Hormone%20(GnRH)%20and%20the%20GnRH%20Receptor%20(GnRHR)/item/284.
Дата обращения 04.03.2016.73)Schally, A.V. Luteinizing hormone-releasing hormone analogs: theirimpact on the control of tumorigenesis [Text] / A.V. Schally // Peptides. — 1999. —Vol. 20. — No 10. — P. 1247—1262.74)Moradi, S.V. Evaluation of the biological properties and the enzymaticstability of glycosylated luteinizing hormone-releasing hormone analogs [Text] / S.V.Moradi, P. Varamini, I.
Toth // AAPS J. — 2015. — Vol. 17. — No 5. — P. 1135—1143.75)Walters, K. Luteinizing hormone-releasing hormone I (LHRH-I) and itsmetabolite in peripheral tissues [Text] / K. Walters, I.N. Wegorzewska, Y.-P. Chin,M.G. Parikh, T.J. Wu // Exp. Biol. Med. — 2008. — Vol. 233. — No 2. — P. 123—130.76)Wilson, A.C. Leuprolide acetate: a drug of diverse clinical applications[Text] / A.C. Wilson, S.V. Meethal, R.L. Bowen, C.S. Atwood // Expert Opin. Investig.Drugs.
— 2007. — Vol. 16. — No 11. — P. 1851—1863.77)Zoladex. [Электронный Ресурс] // Highlights Of Prescribing Information :—[сайт]:URL:http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020578s034,020578s035lbl.pdf. Дата обращения: 10.03.2016.78)Approval package for: application number NDA 21-732 [ЭлектронныйРесурс] // Center for drug evaluation and research : [сайт]: — URL:144http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021732s000_Vantas_ClinPharmR.pdf.
Дата обращения: 10.03.2016.79)Stop Testosterone (T) at its main source. [Электронный Ресурс] //Firmagon® | Official Site: Advanced Prostate Cancer : [сайт]: — URL:http://www.firmagon.us/#/how-its-designed-to-work. Дата обращения: 10.03.2016.80)Sonesson, A. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey [Text] / A. Sonesson,W.
Koechling, J. Stalewski, L.B. Tanko, B.B. Rasmussen // Drug Metab. Dispos. —2011. — Vol. 39. — No 10. — P. 1895—1903.81)Samant, M.P. Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidizedderivatives [Text] / M.P. Samant, R. White, D.J. Hong, G. Croston, P.M. Conn, J.A.Janovick, J. Rivier // J. Med. Chem. — 2007. — Vol.
50. — No 9. — P. 2067—2077.82)Jones, D.A. Metabolism of the anticancer peptide H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2 [Text] / D.A. Jones, J. Cummings, S.P. Langdon, A.J. MacLellan,T. Higgins, E. Rozengurt, J.F. Smyth // Peptides. — 1995. — Vol. 16. — No 5. —P. 777—783.83)Sandberg, B.E. Synthesis and biological properties of enzyme-resistantanalogues of substance P [Text] / B.E. Sandberg, C.M. Lee, M.R. Hanley, L.L. Iversen// Eur.
J. Biochem. — 1981. — Vol. 114. — No 2. — P. 329—337.84)Bruehlmeier, M. Stabilization of neurotensin analogues: effect on peptidecatabolism, biodistribution and tumor binding [Text] / M. Bruehlmeier, E.G. Garayoa,A. Blanc, B. Holzer, S. Gergely, D. Tourwe, P.A. Schubiger, P. Blauenstein // Nucl.Med. Biol. — 2002. — Vol. 29. — No 3. — P. 321—327.85)Kawai, M.
Preparation and opioid activities of N-methylated analogs of [D-Ala2,Leu5]enkephalin [Text] / M. Kawai, N. Fukuta, N. Ito, T. Kagami, Y. Butsugan,M. Maruyama, Y. Kudo // Int. J. Pept. Protein Res. — 1990. — Vol. 35. — No 5. —P. 452—459.86)Haviv, F. Effect of N-methyl substitution of the peptide bonds inluteinizing hormone-releasing hormone agonists [Text] / F. Haviv, T.D. Fitzpatrick,145R.E. Swenson, C.J.
Nichols, N.A. Mort, E.N. Bush, G. Diaz, G. Bammert, A. Nguyen,N.S. Rhutasel, H.N. Nellans, D.J. Hoffman, E.S. Johnson, J. Greer // J. Med. Chem. —1993. — Vol. 36. — No 3. — P. 363—369.87)Biondi, L. Synthesis, conformation and biological activity of dermorphinand deltorphin I analogues containing N-alkylglycine in place of residues in position 1,3, 5 and 6 [Text] / L. Biondi, E.
Giannini, F. Filira, M. Gobbo, M. Marastoni, L. Negri,B. Scolaro, R. Tomatisc, R. Rocchi // J. Pept. Sci. — 2003. — Vol. 9. — No 10. —P. 638—648.88)Pollaro, L. Strategies to prolong the plasma residence time of peptide drugs[Text] / L. Pollaro, C. Heinis // Med. Chem.
Comm. — 2010. — Vol. 1. — No 5. —P. 319—324.89)Tal-Gan, Y. Metabolic stability of peptidomimetics: N-methyl and azaheptapeptide analogs of a PKB/Akt inhibitor [Text] / Y. Tal-Gan, N.S. Freeman, S.Klein, A. Levitzki, C. Gilon // Chem. Biol. Drug Des. — 2011. — Vol.
78. — No 5. —P. 887—892.90)Spatola, A.F. In chemistry and biochemistry of peptides and proteins [Text]/ A.F. Spatola, B. Weinstein // New-York.: Marcel Dekker. — 1983. — Vol. 7. —P. 267—357.91)Adessi, C. Converting a peptide into a drug: strategies to improve stabilityand bioavailability [Text] / C. Adessi, C. Soto // Curr. Med.
Chem. — 2009. — Vol. 9.— No 9. — P. 963—978.92)Proulx, C. Azapeptides and their therapeutic potential [Text] / C. Proulx, D.Sabatino, R. Hopewell, J. Spiegel, Y. Garcia Ramos, W.D. Lubell // Future Med. Chem.— 2011. — Vol. 3. — No 19. — P. 139—164.93)Patch, J.A. Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers [Text] / J.A. Patch, A.E. Barron // Curr. Opin. Chem.Biol. — 2002. — Vol.
6. — No 6. — P. 872—877.94)Fowler, S.A. Structure-function relationships in peptoids: recent advancestoward deciphering the structural requirements for biological function [Text] / S.A.146Fowler, H.E. Blackwell // Org. Biomol. Chem. — 2009. — Vol. 7. — No 12. —P. 1508—15024.95)Proulx, C. Méthodologie pour la synthèse combinatoire d’azapeptides:application à la synthèse d’analogues aza-GHRP-6 en tant que ligands du récepteurCD36 [Text] : Electronic thesis or dissertation, chemistry : degree granted 03.12.2012 /C.
Proulx // Montreal. — 2012. — P. 4—5.96)Zega, A. Azapeptides as pharmacological agents [Text] / A. Zega // Curr.Med. Chem. — 2005. — Vol. 12. — No 5. — P. 589—597.97)Dutta, A.S. Polypeptides. Part XIV. A comparative study of the stabilitytowards enzymes of model tripeptides containing alpha-aza-amino-acids, L-aminoacids, and D-amino-acids [Text] / A.S. Dutta, M.B. Giles // J. Chem. Soc. Perkin 1. —1976. — Vol. 2.
— P. 244—248.98)AstraZenecaZOLADEX® (goserelin acetate implant) [Электронный ресурс] //PharmaceuticalsLP:[сайт]:—URL:http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=4532. Датаобращения: 21.02.2016.99)Cockshott, I.D. Clinical pharmacokinetics of goserelin [Text] / I.D.Cockshott // Clin. Pharmacokinet. — 2000. — Vol. 39. — No 1. — P. 27―48.100) Farajallah, A. Antiviral Drugs [Text] / A. Farajallah, R. Bunch, M.N.A.Todd // USA: John Wiley & Sons, Inc. — 2011. — P.
3—17.101) Lunt B., Olivier G., Pavinatto F., Zuckermann R., Investigation of peptoidthin films and their potential use in a biosensor [Электронный ресурс] // ElectricalEngineering and Computer Sciences University of California at Berkeley: [сайт]: —URL: https://www.eecs.berkeley.edu/Pubs/TechRpts/2013/EECS-2013-111.html. Датаобращения: 21.02.2016.102) Hooks, J.C.
Development of homomultimers and heteromultimers of lungcancer-specific peptoids [Text] / J.C. Hooks, J.P. Matharage, D.G. Udugamasooriya //Biopolymers. — 2011. — Vol. 96. — No 12. — P. 567—577.147103) Zuckermann, R.N. Peptoids as potential therapeutics [Text] / R.N.Zuckermann, T. Kodadek // Curr. Opin. Mol. Ther. — 2011. — Vol. 11. — No 5. —P. 299—307.104) Miller, S.M. Proteolytic studies of homologous peptide and N-substitutedglycine peptoid oligomers [Text] / S.M. Miller, R.J. Simon, S. Ng, R.N. Zuckermann,J.M.
Kerr, W.H. Moos // Bioorg. Med. Chem. Lett. — 1994. — Vol. 4. — No 12. —P. 2657—2662.105) Miller, S.M. Comparison of the proteolytic susceptibilities of homologousL-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers[Text] / S.M. Miller, R.J. Simon, S. Ng, R.N. Zuckermann, J.M. Kerr, W.H.
Moos //Drug Dev. Res. — 1995. — Vol. 35. — No 1. — P. 20—32.106) Simon, R.J. Using peptoid libraries [Oligo N-substituted glycines] for drugdiscovery [Text] / R.J. Simon, E.J. Martin, S.M. Miller, R.N. Zuckermann, J.M. Blaney// Techniqies in protein chemistry V — 1994. — P. 533—539.107) Wang, Y. Absorption and disposition of a tripeptoid and a tetrapeptide inthe rat [Text] / Y. Wang, H.
Lin, R. Tullman, C.F. Jewell, M.L. Weetall, F.L. Tse //Biopharm. Drug Dispos. — 1999. — Vol. 20. — No 2. — P. 69—75.108) Marraud, M. Modifications of the amide bond and conformationalconstraints in pseudopeptide analogues [Text] / M. Marraud, V. Dupont, V. Grand, S.Zerkout, A. Lecoq, G. Boussard, J. Vidal, A. Collet, A. Aubry // Biopolymers. — 1993.— Vol. 33. — No 7. — P. 1135—1148.109) Weiner, D.B. Biologically active peptides: Design, synthesis and utilization[Text] / D.B. Weiner, W.V.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
